Miromatrix CEO Jeff Ross Shares the Bold Plan to Eliminate the Organ Transplant Waiting List
Jan 11, 2019
31:21
forum Ask episode
view_agenda Chapters
auto_awesome Transcript
info_circle Episode notes
Miromatrix straddles the line between biotech and medtech. The start-up is developing a line of “ghost organs” that can be used in humans. The technology is moving fast, and Ross hopes to have clinical trials up and running by the end of 2020. The future is here. Also, I’ll announce a keynote speaker for the May 30 Medtech Conference.
Medtech Talk